Noticias y Actividades de Seres Therapeutics
Presencia
Seres Therapeutics es una de las ...
Seres Therapeutics es una empresa que cotiza bajo el símbolo de cotización MCRB (US).
Ejecutivos
Ver el organigrama con sus 23 ejecutivos principales
Biografías más buscadas en Seres Therapeutics
- Eric Shaff, Director, President and Chief Executive Officer
- Stephen Berenson, Chairman of the Board
- Paul Biondi, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Seres Therapeutics.
Biotecnología
Seres Therapeutics tiene 2.339 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Biogen (Estados Unidos).
Popular M&A news in Biotecnología
- Jade Biosciences and Aerovate Therapeutics have announced they will merge (publicado el 30 de abril de 2025)..
- Deepull acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 29 de abril de 2025).
- Biolinq acaba de anunciar una recaudación de fondos de 100 millones de dólares. (publicado el 23 de abril de 2025).
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Seres Therapeutics
- Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference | Seres Therapeutics
- Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022 | Seres Therapeutics
- Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock | Seres Therapeutics
- Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection | Seres Therapeutics
- Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Presents Phase III Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting | Seres Therapeutics
- Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates | Seres Therapeutics
- Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022 | Seres Therapeutics
- View more press releases Close
Redes sociales sobre Seres Therapeutics
- Seres Therapeutics en Wikipedia, Google News y Yahoo Finance
- Seres Therapeutics en LinkedIn, Twitter y YouTube
